

Karin Sundfeldt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5810495/publications.pdf>

Version: 2024-02-01

54
papers

1,657
citations

331670

21
h-index

302126

39
g-index

56
all docs

56
docs citations

56
times ranked

3016
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	178
2	Cell-cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule. <i>Molecular and Cellular Endocrinology</i> , 2003, 202, 89-96.	3.2	104
3	Mitochondrial protein enriched extracellular vesicles discovered in human melanoma tissues can be detected in patient plasma. <i>Journal of Extracellular Vesicles</i> , 2019, 8, 1635420.	12.2	104
4	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	12.8	88
5	TGF- β 2 isoforms induce EMT independent migration of ovarian cancer cells. <i>Cancer Cell International</i> , 2014, 14, 72.	4.1	82
6	A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass. <i>Gynecologic Oncology</i> , 2015, 138, 640-646.	1.4	78
7	High throughput proteomics identifies a high-accuracy 11 plasma protein biomarker signature for ovarian cancer. <i>Communications Biology</i> , 2019, 2, 221.	4.4	77
8	Differences in expression patterns of the tight junction proteins, claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours. <i>International Journal of Cancer</i> , 2006, 118, 1884-1891.	5.1	71
9	Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass. <i>Journal of Gynecologic Oncology</i> , 2011, 22, 244.	2.2	69
10	The Chemotactic Cytokine Interleukin-8 - A Cyst Fluid Marker for Malignant Epithelial Ovarian Cancer?. <i>Gynecologic Oncology</i> , 1998, 71, 420-423.	1.4	63
11	A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. <i>Gynecologic Oncology</i> , 2018, 151, 159-165.	1.4	62
12	Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 131, 52-58.	1.4	57
13	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. <i>Modern Pathology</i> , 2019, 32, 1834-1846.	5.5	54
14	Immunohistochemical validation of COL3A1, GPR158 and PITHD1 as prognostic biomarkers in early-stage ovarian carcinomas. <i>BMC Cancer</i> , 2019, 19, 928.	2.6	46
15	Potential tumor biomarkers identified in ovarian cyst fluid by quantitative proteomic analysis, iTRAQ. <i>Clinical Proteomics</i> , 2013, 10, 4.	2.1	37
16	Genital Chronic Graft-versus-Host Disease in Females: A Cross-Sectional Study. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 806-811.	2.0	32
17	Diagnostic potential of tumor DNA from ovarian cyst fluid. <i>ELife</i> , 2016, 5, .	6.0	30
18	Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b. <i>BMC Cancer</i> , 2017, 17, 303.	2.6	30

#	ARTICLE	IF	CITATIONS
19	The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors. <i>PLoS ONE</i> , 2015, 10, e0130197.	2.5	27
20	Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry. <i>Frontiers in Oncology</i> , 2020, 10, 162.	2.8	27
21	Ovarian cyst fluid is a rich proteome resource for detection of new tumor biomarkers. <i>Clinical Proteomics</i> , 2012, 9, 14.	2.1	23
22	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. <i>Modern Pathology</i> , 2021, 34, 194-206.	5.5	21
23	Consideration should be given to smoking, endometriosis, renal function (eGFR) and age when interpreting CA125 and HE4 in ovarian tumor diagnostics. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1954-1962.	2.3	21
24	A two-step strategy for identification of plasma protein biomarkers for endometrial and ovarian cancer. <i>Clinical Proteomics</i> , 2018, 15, 38.	2.1	20
25	A prospective study of female genital chronic graft-versus-host disease symptoms, signs, diagnosis and treatment. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2018, 97, 1122-1129.	2.8	19
26	Sociodemographic disparities in stage-specific incidences of endometrial cancer: a registry-based study in West Sweden, 1995-2016. <i>Acta Oncologica</i> , 2019, 58, 845-851.	1.8	19
27	Univariate and classification analysis reveals potential diagnostic biomarkers for early stage ovarian cancer Type 1 and Type 2. <i>Journal of Proteomics</i> , 2019, 196, 57-68.	2.4	15
28	Long-term survival in obese patients after robotic or open surgery for endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 158, 673-680.	1.4	15
29	Validated biomarker assays confirm that <i>ARID1A</i> loss is confounded with <i>MMR</i> deficiency, <i>CD8⁺ TIL</i> infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. <i>Journal of Pathology</i> , 2022, 256, 388-401.	4.5	15
30	Integrative genomics approach identifies molecular features associated with early-stage ovarian carcinoma histotypes. <i>Scientific Reports</i> , 2020, 10, 7946.	3.3	14
31	Early inflammatory response in epithelial ovarian tumor cyst fluids. <i>Cancer Medicine</i> , 2014, 3, 1302-1312.	2.8	12
32	Patient-reported lower urinary tract symptoms after hysterectomy or hysteroscopy: a study from the Swedish Quality Register for Gynecological Surgery. <i>International Urogynecology Journal</i> , 2017, 28, 1341-1349.	1.4	12
33	Next Generation Plasma Proteomics Identifies High-Precision Biomarker Candidates for Ovarian Cancer. <i>Cancers</i> , 2022, 14, 1757.	3.7	12
34	Hysterectomy and opportunistic salpingectomy (HOPPSA): study protocol for a register-based randomized controlled trial. <i>Trials</i> , 2019, 20, 10.	1.6	11
35	Symptoms within somatization after sexual abuse among women: A scoping review. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 758-767.	2.8	11
36	Transcriptomic and genomic profiling of early-stage ovarian carcinomas associated with histotype and overall survival. <i>Oncotarget</i> , 2018, 9, 35162-35180.	1.8	10

#	ARTICLE	IF	CITATIONS
37	Nanoparticle-aided glycovariant assays to bridge biomarker performance and ctDNA results. <i>Molecular Aspects of Medicine</i> , 2020, 72, 100831.	6.4	9
38	Lifestyle and Chronic Pain in the Pelvis: State of the Art and Future Directions. <i>Journal of Clinical Medicine</i> , 2021, 10, 5397.	2.4	8
39	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 855-871.	2.8	8
40	Protein Detection Using the Multiplexed Proximity Extension Assay (PEA) from Plasma and Vaginal Fluid Applied to the Indicating FTA Elute Micro Cardâ„¦. <i>Journal of Circulating Biomarkers</i> , 2016, 5, 9.	1.3	7
41	Ovarian Blood Sampling Identifies Junction Plakoglobin as a Novel Biomarker of Early Ovarian Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1767.	2.8	7
42	Increased Diagnostic Accuracy of Adnexal Tumors with A Combination of Established Algorithms and Biomarkers. <i>Journal of Clinical Medicine</i> , 2020, 9, 299.	2.4	7
43	Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers. <i>Proteomes</i> , 2021, 9, 25.	3.5	6
44	Diagnostic potential of nanoparticle aided assays for <scp>MUC16</scp> and <scp>MUC1</scp> glycovariants in ovarian cancer. <i>International Journal of Cancer</i> , 2022, 151, 1175-1184.	5.1	6
45	Preoperative Fasting and General Anaesthesia Alter the Plasma Proteome. <i>Cancers</i> , 2020, 12, 2439.	3.7	5
46	Populationâ€based cohort study of the effect of endometrial cancer classification and treatment criteria on longâ€term survival. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 138, 183-189.	2.3	4
47	Late followâ€up of genital and ophthalmologic chronic graftâ€vsâ€host disease in females after allogeneic stem cell transplantation. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2022, 101, 364-373.	2.8	4
48	Evaluation of Sialyl-Lactotetra as a Marker for Epithelial Ovarian Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 561888.	2.8	3
49	Analysis of blood group antigens on MUC5AC in mucinous ovarian cancer tissues using <i>in situ</i> proximity ligation assay. <i>Glycobiology</i> , 2021, 31, 1464-1471.	2.5	3
50	DNA ploidy status, S-phase fraction, and p53 are not independent prognostic factors for survival in endometrioid endometrial carcinoma FIGO stage Iâ€III. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 305-311.	2.5	1
51	Sulfation of O-glycans on Mucin-type Proteins From Serous Ovarian Epithelial Tumors. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100150.	3.8	1
52	Targeted Selected Reaction Monitoring Verifies Histology Specific Peptide Signatures in Epithelial Ovarian Cancer. <i>Cancers</i> , 2021, 13, 5713.	3.7	1
53	A serum biomarker panel including kallikreins to predict ovarian cancer prognosis and response to chemotherapy. <i>Expert Review of Obstetrics and Gynecology</i> , 2009, 4, 21-23.	0.4	0
54	Reply: HE4, CA-125, and cystic ovarian mass. <i>Journal of Gynecologic Oncology</i> , 2012, 23, 133.	2.2	0